Cargando…
LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer
LKB1 is among the most frequently altered tumor suppressors in lung adenocarcinoma. Inactivation of Lkb1 accelerates the growth and progression of oncogenic KRAS-driven lung tumors in mouse models. However, the molecular mechanisms by which LKB1 constrains lung tumorigenesis and whether the cancer s...
Autores principales: | Murray, Christopher W., Brady, Jennifer J., Han, Mingqi, Cai, Hongchen, Tsai, Min K., Pierce, Sarah E., Cheng, Ran, Demeter, Janos, Feldser, David M., Jackson, Peter K., Shackelford, David B., Winslow, Monte M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885825/ https://www.ncbi.nlm.nih.gov/pubmed/35228570 http://dx.doi.org/10.1038/s41467-022-28619-8 |
Ejemplares similares
-
Targeting LKB1 in cancer – exposing and exploiting vulnerabilities
por: Momcilovic, M, et al.
Publicado: (2015) -
A new system for multiplexed mosaic analysis of gene function in the mouse
por: Cai, Hongchen, et al.
Publicado: (2022) -
LKB1 deficiency-induced metabolic reprogramming in tumorigenesis and non-neoplastic diseases
por: Zhang, Yanghe, et al.
Publicado: (2020) -
LKB1 specifies neural crest cell fates through pyruvate-alanine cycling
por: Radu, Anca G., et al.
Publicado: (2019) -
How does C/EBPα speed up cell reprogramming?
por: Sardina, Jose Luis, et al.
Publicado: (2016)